title: Crossover study with cisplatin or carboplatin in advanced ovarian cancer.
abstract: Fifty-seven patients who had progressed during or relapsed after randomized first-line combination chemotherapy containing cisplatin or carboplatin were entered into a crossover study in which the analog not previously assigned was administered alone as salvage treatment. Carboplatin and cisplatin were administered at doses of 400 and 100 mg/m2, respectively, every 28 days. Among the 24 patients enrolled in the cisplatin arm, 6 (25%) objective responses (ORs) (3 complete, 3 partial) were observed, whereas 3 partial responses were obtained in the 33 carboplatin-treated patient (9%). Analysis of results, according to response to first-line chemotherapy, demonstrated that the patients who progressed were sensitive only to cisplatin second-line treatment (OR: 3/12), with no responders among carboplatin-treated patients (OR: 0/11). All patients were treated on an outpatient basis and therapy-related toxic effects were mild, consisting chiefly of myelosuppression, and more frequent in the carboplatin group. In our opinion, carboplatin 400 mg/m2 per cycle is scarcely effective in patients with refractory or relapsed ovarian cancer pretreated with cisplatin regimens, whereas cisplatin 100 mg/m2 per cycle appears to be an effective salvage therapy even in patients not responding to carboplatin. The dose of carboplatin should be further escalated especially in refractory patients.
authors.affiliation: Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Repetto
authors.forename: S
authors.initials: S
authors.lastname: Chiara
authors.forename: S
authors.initials: S
authors.lastname: Mammoliti
authors.forename: T
authors.initials: T
authors.lastname: Guido
authors.forename: M
authors.initials: M
authors.lastname: Bruzzone
authors.forename: V
authors.initials: V
authors.lastname: Secondo
authors.forename: G
authors.initials: G
authors.lastname: Donadio
authors.forename: F
authors.initials: F
authors.lastname: Odicino
authors.forename: N
authors.initials: N
authors.lastname: Ragni
authors.forename: P F
authors.initials: PF
authors.lastname: Conte
mesh_terms: D016190:Carboplatin / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*
chemical_list: D016190:Carboplatin; D002945:Cisplatin